Peter S Galatin

Summary

Publications

  1. ncbi Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
    Peter S Galatin
    Department of Medicine, Oncology, Stanford University School of Medicine, Stanford, CA, USA
    Invest New Drugs 29:971-7. 2011

Collaborators

Detail Information

Publications1

  1. ncbi Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
    Peter S Galatin
    Department of Medicine, Oncology, Stanford University School of Medicine, Stanford, CA, USA
    Invest New Drugs 29:971-7. 2011
    ..The present study was designed to determine the maximum tolerated dose (MTD) of oblimersen (antisense Bcl-2) and gemcitabine when administered to patients with refractory malignancies...